S1826- A Phase III, Randomized Study Of Nivolumab (Opdivo) Plus Avd Or Brentuximab Vedotin (Adcetris) Plus Avd In Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Posted Date: Apr 23, 2020
- Investigator: Tahir Latif
- Specialties: Cancer, Lymphoma, Oncology
- Type of Study: Drug
The goal of this study is to compare the progression-free survival (PFS) in patients with newly diagnosed advanced stage classical Hodgkin lymphoma randomized to N-AVD (nivolumab, doxorubicin,vinblastine, dacarbazine) versus that obtained with BV-AVD (brentuximab vedotin,doxorubicin, vinblastine, dacarbazine).
Criteria:
To Be Eligible: Must Have Diagnosis Of Hodgkins Lymphoma, Adequate Organ Function, No Previous Therapy For Study Cancer, No Hx Of Organ Transplant, No Active Intercurrent Illness Or Infection
Keywords:
Lymphoma
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com